GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » EV-to-Revenue

Prescient Therapeutics (ASX:PTX) EV-to-Revenue : (As of Jun. 28, 2025)


View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Prescient Therapeutics's enterprise value is A$28.67 Mil. Prescient Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil. Therefore, Prescient Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Prescient Therapeutics's EV-to-Revenue or its related term are showing as below:

ASX:PTX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.685
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-28), Prescient Therapeutics's stock price is A$0.046. Prescient Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00. Therefore, Prescient Therapeutics's PS Ratio for today is .


Prescient Therapeutics EV-to-Revenue Historical Data

The historical data trend for Prescient Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics EV-to-Revenue Chart

Prescient Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prescient Therapeutics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prescient Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Prescient Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's EV-to-Revenue falls into.


;
;

Prescient Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Prescient Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=28.673/0
=

Prescient Therapeutics's current Enterprise Value is A$28.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prescient Therapeutics  (ASX:PTX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Prescient Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.046/0
=

Prescient Therapeutics's share price for today is A$0.046.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prescient Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics Headlines

No Headlines